Fidelity
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

MCET RSS Feed
Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, locksflooring, roberteliates, HorseShoe Man, Chicago
Search This Board:
Last Post: 4/15/2014 11:12:41 PM - Followers: 603 - Board type: Free - Posts Today: 0

MultiCell Technologies (MCET) 

 

 
OTCQB: Ticker - MCET (U.S. Reporting: SEC Filer) 

Number of shares outstanding: 3,152,360,170

Market Value: $6,304,720 a/o April 02, 2014

Estimated Float: 600,000 a/o March 30, 2004
 

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)
 


Partners

AmarinCorningPhizer


Recent News: March 20, 2014 - MultiCell Technologies Files U.S. and International Patent Applications for the Treatment of Liver Cancer
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has filed additional U.S. and international patent applications covering MCT-485 and its composition of matter, biological targets, mechanism of action, and methods and formulations for therapeutic use. MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in in vitro models of hepatocellular carcinoma.  MCT-485 is thought to target cancer by delivering a cytotoxic and oncolytic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells.  MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer. Press Release >>


Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development

 MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.

                                       MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.

 
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

 
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Therapeutic Candidate

Indication

Discovery Optimization

Preclinical Development

Phase 1

Phase 2

Phase 3

MCT-125

PMSF

         

MCT-465

Cancer

         

MCT-475

Cancer

         

MCT-485

Cancer

         


Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.


MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

MultiCell Technologies Inc. Headquarters

68 Cumberland Street, Suite 301
Woonsocket, RI 02895
Office: (401) 762-0045
Email: info@multicelltech.com
Web: www.multicelltech.com

Find us on Google Maps  
    http://www.facebook.com/MCET.OB  
 


Management

 

 
W. Gerald Newmin, Chairman and Chief Executive Officer
Mr. W. Gerald Newmin joined the Company in June 1995.  Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company.  Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company.  Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies.  Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company.  Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured.  Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive.  Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets.  Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States.  Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003.  Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.

Stephen Chang, PhD (Vice President, Research and Development)
Stephen M. Chang, Ph.D., Director
Dr. Stephen Chang has served as a director of the Company since June 2004.  Dr. Chang has been Chief Scientific Officer (CSO) of Stemgent, Inc. since January 2008.  Prior to joining Stemgent, Dr. Chang served as President and CEO of MultiCell from July 2006 until December 2007, and as President of MultiCell from September 2005 to June 2006.  Prior to joining Multicell, Dr. Chang was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in September 2005.  Prior to joining Astral, Dr. Chang was CSO and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004.  Dr. Chang has also held senior management positions at Chiron and Viagene.  Dr. Chang is currently president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative life saving medications.  Dr. Chang is also a board member of Histogen a privately held company in regenerative medicine.  Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.

Grant Miller,  MBA/CFO
Grant Miller, Director
Mr. Miller, appointed to the Board in 2012, received his B.A. from Loma Linda University in Riverside, CA and an MBA in Finance from the University of San Diego, in San Diego, CA. Mr. Miller is Chief Financial & Operating Officer of Sandel Avionics and has served as Chief Financial Officer of Rapid Bridge, LLC, General Manager & Division Controller of Scubapro, Chief Financial Officer of USA Broadband, Inc., Chief Financial Officer & Senior VP Operations of Alitum, and held several positions with WorldXchange and Time Warner Cable, including International Director of Development in Spain and Portugal, Regional Vice President Finance, Corporate Mergers & Acquisitions Analyst, Manager, Finance and Information Systems and Financial Analysis.

Edward Sigmond
Edward Sigmond, Director
Mr. Edward Sigmond has served as a director of the Company since May 2000.  Mr. Sigmond has been in sales, marketing and operations management for the past 20 years.  Mr. Sigmond has served as president of Kestrel Holdings, Inc., a holding company, since its inception in 1997.  Mr. Sigmond served as president of Kestrel Development, a Texas based real estate development company, from 1993 to 1998 when it was dissolved.  Mr. Sigmond studied Marketing and Chemistry at Duquesne University.

Thomas A. Page, Director
Mr. Thomas Page has served as a director of the Company since September 2003.  Mr. Page is Director Emeritus and former Chairman of the Board and CEO of Enova Corporation and San Diego Gas and Electric Company (now part of Sempra Energy).  Prior to the formation of Sempra Energy Corporation as a holding company in 1996, at various times Mr. Page was SDG&E’s chairman, president and CEO and  held one or more of these positions until his retirement in 1998.  Mr. Page joined SDG&E in 1978 as executive vice president and COO.  In 1981, he was elected president and CEO and added the chairmanship in 1983.  Mr. Page has been active in numerous industrial, community and governmental associations and has funded medical research.  He is a director of the San Diego Regional Economic Development Corporation, Community National Bank, Sys Technologies and is an advisory director of Sorrento Ventures.  Mr. Page earned a Bachelor of Science degree in civil engineering, a masters degree in industrial administration and was awarded a doctorate in management, all from Purdue University.  Mr. Page has been licensed as an engineer and as a certified public accountant (CPA).  Mr. Page also serves on the University of California Presidents Council on the National Laboratories.


Scientific Advisors

Alan Tuchman, M.D.
Dr. Tuchman is concurrently in private practice and is Clinical Professor of Neurology at New York Medical College.  He is also the Principal of a healthcare and neuroscience consulting firm.  From 1997 to 2001, Dr. Tuchman was Senior Vice President of Equity Research for Oscar Gruss & Son (Member of the New York Stock Exchange), New York, New York, where he conducted investment research in medical and biotechnology and helped develop marketing strategies for healthcare companies.  Prior to this, he was Vice Dean of Clinical Affairs for New York Medical College where he developed and directed clinical care and medical education policy for 29 affiliated hospitals and served as Professor and Vice Chairman and Program Director for Neurology Residency in the Department of Neurology at the same institution.  At the Lincoln Medical and Mental Health Center, Dr. Tuchman held the positions of Medical Director for the 560-bed hospital from 1990 to 1991 and Director of the Department of Neurology from 1979 to 1994.  Serving in the United States Air Force as Major, he was Chief of Neurology Service for a 16-state region.  Dr. Tuchman earned his B.S. in Chemistry in 1968 from the City College of New York, his M.D. in 1972 from the University of Cincinnati College of Medicine, and his MBA from Columbia University in 1996. He completed his internship at New York Medical College and his residency at the Mount Sinai Hospitals Department of Neurology.  Dr. Tuchman was a clinical fellow in multiple sclerosis at the Albert Einstein College of Medicine Department of Neurology.  Dr. Tuchman is certified by the American Board of Psychiatry and Neurology and the American Society of Neurorehabilitation and is licensed in New York, New Jersey and Ohio.  Dr. Tuchman served as the President of the Epilepsy Society of Southern New York from 1987 1992.

 



www.ThinkingAlpha.com

PostSubject
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#31933  Sticky Note This is huge MCT-485 has demonstrated in in redsox17 03/20/14 09:50:05 AM
#27347  Sticky Note PATENT INFORMATION roberteliates 03/28/13 07:50:04 AM
#35311   Can anyone provide a link to the Patent MCT-125 Dip66 04/15/14 11:12:41 PM
#35310   Recap: Great Read! Dip66 04/15/14 10:49:09 PM
#35309   The part people are missing is that there 05181992J03huA 04/15/14 09:51:31 PM
#35308   MCET is not losing anything. There is always ttmasher 04/15/14 09:30:02 PM
#35307   MCET, will go much higher! Read the "NEWS" ttmasher 04/15/14 09:23:32 PM
#35306   What a crappy day , still holding but damondon 04/15/14 09:00:19 PM
#35305   Just out of curiosity does anyone have a Dip66 04/15/14 08:44:27 PM
#35303   I agree on first read it is discouraging veto 04/15/14 07:14:01 PM
#35302   HShoe Let them make a response to the alleged bluejacket6 04/15/14 07:11:54 PM
#35301   I have 6 years and 4606 posts and HorseShoe Man 04/15/14 07:08:36 PM
#35300   On January 31, 2014, Xenogenics received a Notice HorseShoe Man 04/15/14 06:19:27 PM
#35299   MCET Big $$$ right around to corner ^^ Impervious 04/15/14 05:52:29 PM
#35298   Please explain to me what he's talking about bluejacket6 04/15/14 05:38:53 PM
#35297   Thanks. I'm sticking. 100-200% gain is not enough illionaire 04/15/14 05:36:58 PM
#35296   I believe MultiCell has the winning patents. This Dip66 04/15/14 05:21:33 PM
#35295   I'm not but I guarantee there will be HorseShoe Man 04/15/14 05:21:10 PM
#35294   MultiCell Technologies, Inc. Dip66 04/15/14 05:17:28 PM
#35293   Let's stay on topic here not a thing Dip66 04/15/14 05:14:40 PM
#35291   I second that HUH?? bluejacket6 04/15/14 04:10:21 PM
#35290   Huh?? floydborga 04/15/14 04:08:22 PM
#35288   Strange, all of a sudden there's no trading.. floydborga 04/15/14 02:50:11 PM
#35287   Yep kind of want it at this level Turtledip 04/15/14 02:11:29 PM
#35286   Seems the bleeding has stopped.. floydborga 04/15/14 02:09:21 PM
#35285   Hold on tight my fellow investors I'm adding Turtledip 04/15/14 02:04:00 PM
#35284   Also adding here .0012 ^^ Impervious 04/15/14 01:54:20 PM
#35283   waiting for the 11s myself peacbywar 04/15/14 01:48:39 PM
#35282   Loading up on these 12 and 13s these Mopar10 04/15/14 01:46:52 PM
#35281   what did i miss? why is this falling Tambra3077 04/15/14 01:09:47 PM
#35280   Just a quick look back, funny how a Impervious 04/15/14 01:06:38 PM
#35279   Mms doing a great job keeping this from HorseShoe Man 04/15/14 01:01:30 PM
#35278   MCET is just like a sling shot right Impervious 04/15/14 01:01:29 PM
#35277   That's a major hit to MCET and the shareholders. HorseShoe Man 04/15/14 12:56:03 PM
#35276   12 / 13 ------------ -------------------- --------------------- ------------- ManyYearsOTC 04/15/14 12:48:22 PM
#35275   Notice the heavy chopping on the 13's.. Those are ManyYearsOTC 04/15/14 12:28:25 PM
#35274   Sure can. I was just reading between the bluejacket6 04/15/14 12:22:17 PM
#35273   Short one week long the next... Looking at some Cocokimmy 04/15/14 12:20:30 PM
#35272   Green--- and I'm not bias at all regarding ManyYearsOTC 04/15/14 12:19:08 PM
#35271   Nothing has change in this stock in the bluejacket6 04/15/14 12:16:44 PM
#35270   My magic 8 ball says green. She'll bounce illionaire 04/15/14 12:04:13 PM
#35269   Chime in please - Are we closing in Impervious 04/15/14 11:52:46 AM
#35268   Just as it expired today and the last TraderpennyX 04/15/14 11:43:20 AM
#35267   Notice that split second *Billion* on the ASK ManyYearsOTC 04/15/14 11:37:59 AM
#35266   Your welcome--- Hey--- That was some post... I would never write ManyYearsOTC 04/15/14 11:30:57 AM
#35265   The truth is if you want to get TraderpennyX 04/15/14 10:56:14 AM
#35264   A while back you Pm'ed me..you asked a ManyYearsOTC 04/15/14 10:55:32 AM
#35263   I don't see why... ManyYearsOTC 04/15/14 10:47:34 AM
#35262   all youneed is discipline with this stocks and D-Tank 04/15/14 10:40:07 AM
#35261   I have made good money on MCET this ttmasher 04/15/14 10:39:13 AM
#35260   No panic sellers go with the drop in ttmasher 04/15/14 10:36:48 AM
#35259   Sure--- ok--- hey enjoy your day.. Keep on topic-- ManyYearsOTC 04/15/14 10:34:34 AM
PostSubject